TARA-002
Non-Muscle Invasive Bladder Cancer (NMIBC), BCG-unresponsive carcinoma in situ (CIS) with/without papillary tumors
Key Facts
About Protara Therapeutics
Protara Therapeutics is a publicly traded biotech focused on advancing novel therapies for rare diseases and cancer. Its pipeline leverages proprietary delivery platforms, including an intravesical delivery system for bladder cancer and an intravenous phospholipid substrate for IFALD. The company's strategy centers on addressing significant unmet medical needs in specialized therapeutic areas with high-value potential.
View full company profileAbout Protara Therapeutics
Protara Therapeutics is a publicly traded biotech focused on advancing novel therapies for rare diseases and cancer. Its pipeline leverages proprietary delivery platforms, including an intravesical delivery system for bladder cancer and an intravenous phospholipid substrate for IFALD. The company's strategy centers on addressing significant unmet medical needs in specialized therapeutic areas with high-value potential.
View full company profile